Pilot study of incretin analogs as new therapeutics for Friedreich's Ataxia.

CUB - Hôpital Erasme0 个研究点开始时间: 2014年9月8日最近更新: 2014年11月10日

试验速览

暂无简介。

•1. Male/female patients with FRDA diagnosed by confirmed genetic testing
•2. Age 18 years to 70 years
•3. Women who are not pregnant or breast feeding, and who do not intend to become pregnant. Women of childbearing potential who must use a reliable contraceptive method and must provide a negative urine pregnancy test at entry into the study
•4. Stable doses of all medications for 30 days prior to study entry and for the duration of the study.
•5. Patient’s written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Current or history of acute or chronic pancreatitis
•2. History of gastric or other major bleeding, thyroid neoplasia, hypothyroidism or hyperthyroidism
•3. Subjects who have experienced side-effects previously from GLP-1 analogs
•4. Use of another investigational product in the past 28 days
•5. Current insulin treatment

发起方

CUB - Hôpital Erasme